The financials
Artivion, Inc. by the numbers
Artivion, Inc. (AORT) reported revenue of $116M in Q1 2026 (quarter ended March 31, 2026), up 18% from the same quarter a year earlier. That came with a gross margin of 65% and net income of $1.4M (1.2% of revenue). For the full year FY2025, revenue was $441M (+14% year on year) and net income $9.8M. Its largest product in 2026-Q1 was Aortic Stent Grafts at $44M, 38% of the disclosed total, just ahead of On X at 22%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $116M | $99M | +18% |
| Gross profit | $75M | $64M | +19% |
| Operating income | $5.8M | $2.1M | +170% |
| Net income | $1.4M | −$505K | to a profit |
| Diluted EPS | $0.03 | −$0.01 | to a profit |
| Product | Revenue | Share |
|---|---|---|
| Aortic Stent Grafts | $44M | 38% |
| On X | $26M | 22% |
| Preservation Services | $25M | 21% |
| Surgical Sealants | $19M | 16% |
| Other Products | $2.3M | 2.0% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $116.3M (+2.6%)
Preservation Services grew +23% year on yearOther Products -9.0% year on year
Segment Latestquarter on quarteryear on year
- Aortic Stent Grafts$44.4M$44.4MQoQ +12%year on year +21%+12%+21%
- On X$26.0M$26.0MQoQ -3.2%year on year +20%-3.2%+20%
- Preservation Services$24.9M$24.9MQoQ -3.2%year on year +23%-3.2%+23%
- Surgical Sealants$18.8M$18.8MQoQ -0.47%year on year +3.9%-0.47%+3.9%
- Other Products$2.3M$2.3MQoQ -4.2%year on year -9.0%-4.2%-9.0%